Blood pressure medications and cancer is not interlinked
By Ishika Sahni
According to the latest research presented at ESC Congress 2020, blood pressure lowering does not increase the risk of cancer. This research was happening to reassure the citizens of their safety. Both the diseases are not interlinked.
According to the study of author Emma Copland, an epidemiologist at the University of Oxford, UK, that People should assure that anti-hypertensive drug with respect to cancer, which is of utmost concern with their advantages, safeguarding for strokes and heart attacks. The debates for this interconnection of blood pressure and cancer have been continuing for 40 years. The result is very conflicting. Five anti-hypertensive drug classes were investigated. The investigation was done at the risk.
This was the biggest study on cancer results in participants of randomized trials examining antihypertensive medication - across 260,000 people in 31 trials to analyze the potential threat. Examiners of all trials were queried for information on which participants developed cancer.
Plenty of this information has not been published before, creating the latest analysis the most detailed yet. Separately, five antihypertensive drug classes were examined: calcium channel blockers (CCBs), angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors beta-blockers, and diuretics.
The investigators approximated the effect of each drug class on the risk of emerging any type of cancer, of dying from cancer, and of emerging breast, lung, colorectal, skin cancers, and prostate.
They have examined based on age, gender, body size, smoking status and some previous anti-hypertensive medication trials. In 4 years around 15,000 new diagnoses of cancer were found. There was no important effect of any individual drug on any cancer case. Similarly, there is no impact of any anti-hypertensive medication on developing breast, lungs, skin, and cancer etc.
There was no crucial effect on any individual drug class on whole cancer risk. The threat ratio (HR) for any cancer was, 1.06 (95 percent CI 1.01-1.11) with CCBs, 0.97 (95 percent CI 0.93-1.02) with ARBs, 0.99 (95 percent confidence interval [CI]) 0.94-1.04) with ACE inhibitors, 0.98 (95 percent CI 0.89-1.08) with beta-blockers, and 1.01 (95 percent CI 0.95-1.07) with diuretics. When participants were followed completely through the course of each trial, there was no sign that the risk of cancer escalated with longer duration of use of these treatments.